A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of
GDC-0919 and atezolizumab in participants with locally advanced, recurrent, or metastatic
incurable solid malignancy that has progressed after available standard therapy or for which
standard therapy is ineffective, intolerable, or inappropriate. Participants will be enrolled
in two stages, including a dose-escalation stage and an expansion stage.